In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on Nuvalent, with a price target of $111.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anupam Rama has given his Buy rating due to a combination of factors including the promising potential of Nuvalent’s lead programs, NVL-520 and NVL-655, in addressing unmet needs in the oncology market. These programs are focused on ROS1 and ALK NSCLC, which represent a significant market opportunity estimated at $2B-3B+. The data from the ALKOVE-1 study for neladalkib in refractory ALK+ NSCLC is particularly encouraging, showing a high objective response rate and strong activity against resistance mutations, along with a favorable safety profile.
Anupam Rama’s analysis suggests that the positive outcomes in the refractory setting could have beneficial implications for the ongoing front-line study, potentially enhancing the stock’s value. The Overweight rating also reflects the long-term potential of Nuvalent’s pipeline, supported by a discounted cash flow analysis projecting a price target of $111. While there are risks such as potential timeline delays and clinical data outcomes, the overall outlook for Nuvalent remains optimistic, with downside scenarios considered to be low probability events.
In another report released yesterday, Guggenheim also initiated coverage with a Buy rating on the stock with a $122.00 price target.